Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation
Arthritis Research & Therapy · 2024
DOI: 10.1186/s13075-024-03318-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Research & Therapy, 2024. Verfasst von Emily E Holladay und 7 weiteren Autor:innen. Beteiligte Einrichtung: University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35233, USA. Hauptthemen laut MEDLINE: Uric Acid, Gout, Polyethylene Glycols, Urate Oxidase. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases.
Abstract (Originalsprache)
Background/Purpose Little is known about long-term clinical outcomes or urate-lowering (ULT) therapy use following pegloticase discontinuation. We examined ULT use, serum urate (SU), inflammatory biomarkers, and renal function following pegloticase discontinuation.
Methods
We conducted a retrospective analysis of gout patients who discontinued pegloticase using the Rheumatology Informatics System for Effectiveness (RISE) registry from 1/2016 to 6/2022. We defined discontinuation as a gap ≥ 12 weeks after last infusion. We examined outcomes beginning two weeks after last dose and identified ULT therapy following pegloticase discontinuation. We evaluated changes in lab values (SU, eGFR, CRP and ESR), comparing on- treatment (≤ 15 days of the second pegloticase dose) to post-treatment.
Results
Of the 375 gout patients discontinuing pegloticase, median (IQR) laboratory changes following discontinuation were: SU: +2.4 mg/dL (0.0,6.3); eGFR: -1.9 mL/min (− 8.7,3.7); CRP: -0.8 mg/L (-12.8,0.0); and ESR: -4.0 mm/hr (-13.0,0.0). Therapy post-discontinuation included oral ULTs (86.0%), restarting pegloticase (4.5%), and no documentation of ULT (9.5%), excluding patients with multiple same-day prescriptions ( n = 17). Oral ULTs following pegloticase were: 62.7% allopurinol, 34.1% febuxostat. The median (IQR) time to starting/restarting ULT was 92.0 days (55.0,173.0). Following ULT prescribing (≥ 30 days), only 51.0% of patients had SU < 6 mg/dL. Patients restarting pegloticase achieved a median SU of 0.9 mg/dL (IQR:0.2,9.7) and 58.3% had an SU < 6 mg/dL.
Conclusion
Pegloticase treats uncontrolled gout in patients with failed response to xanthine oxidase inhibitors, but among patients who discontinue, optimal treatment is unclear. Based on this analysis, only half of those starting another ULT achieved target SU. Close follow-up is needed to optimize outcomes after pegloticase discontinuation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35233, USA.
- Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, USA.
- University of Nebraska Medical Center and the VA Nebraska-Western Iowa Health Care System, Omaha, NE, USA.
- Horizon Therapeutics Plc (Now Amgen Inc.), Deerfield, IL, USA.
- University of Alabama at Birmingham, 1825 University Blvd, Birmingham, AL, 35233, USA. jrcurtis@uabmc.edu.
- Foundation for Advancing Science, Technology, Education, and Research, Birmingham, AL, USA. jrcurtis@uabmc.edu.
ORCID-Profile: Jeffrey R Curtis
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Holladay, E. E., Mudano, A. S., Xie, F., Zhang, J., Mikuls, T. R., LaMoreaux, B., Padnick-Silver, L., & Curtis, J. R. (2024). Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. Arthritis Research & Therapy. https://doi.org/10.1186/s13075-024-03318-5
Vancouver
Holladay EE, Mudano AS, Xie F, Zhang J, Mikuls TR, LaMoreaux B, et al. Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. Arthritis Research & Therapy. 2024. doi:10.1186/s13075-024-03318-5
BibTeX
@article{Holladay2024,
author = {Holladay, Emily E and Mudano, Amy S and Xie, Fenglong and Zhang, Jingyi and Mikuls, Ted R and LaMoreaux, Brian and Padnick-Silver, Lissa and Curtis, Jeffrey R},
title = {Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation},
journal = {Arthritis Research & Therapy},
year = {2024},
doi = {10.1186/s13075-024-03318-5}
}
EUVIMED